Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsReceivables - NetShares Repurchased
Ratios

Niagen Bioscience (NAGE) Receivables - Other (2017 - 2023)

Niagen Bioscience (NAGE) has disclosed Receivables - Other for 8 consecutive years, with $3.5 million as the latest value for Q1 2023.

  • On a quarterly basis, Receivables - Other rose 52.17% to $3.5 million in Q1 2023 year-over-year; TTM through Mar 2023 was $3.5 million, a 52.17% increase, with the full-year FY2022 number at $3.1 million, up 47.62% from a year prior.
  • Receivables - Other was $3.5 million for Q1 2023 at Niagen Bioscience, up from $3.1 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $3.5 million in Q1 2023 to a low of $89000.0 in Q3 2019.
  • A 5-year average of $1.6 million and a median of $1.3 million in 2021 define the central range for Receivables - Other.
  • Peak YoY movement for Receivables - Other: tumbled 88.16% in 2019, then surged 1023.6% in 2020.
  • Niagen Bioscience's Receivables - Other stood at $800000.0 in 2019, then increased by 12.5% to $900000.0 in 2020, then soared by 133.33% to $2.1 million in 2021, then surged by 47.62% to $3.1 million in 2022, then grew by 12.9% to $3.5 million in 2023.
  • Per Business Quant, the three most recent readings for NAGE's Receivables - Other are $3.5 million (Q1 2023), $3.1 million (Q4 2022), and $2.4 million (Q3 2022).